Can Real-World Wegovy Data Shape MASH Treatment Discussions for Novo Nordisk (NYSE:NVO)?

Sonal Goyal

09 November 2026 04:25 PM AEDT

Can Real-World Wegovy Data Shape MASH Treatment Discussions for Novo Nordisk (NYSE:NVO)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

The PLATINUM-Truveta study included 2,873 adults with MASH who initiated semaglutide 2.4 mg.
At six months, semaglutide 2.4 mg was associated with a mean weight loss of 18.9 pounds, about 8%, compared with resmetirom.
At three months, AST declined 6.7 units with semaglutide, compared with 1.9 units with resmetirom.
Both studies were retrospective, and their results were presented at The Liver Meeting in Denver.

Novo Nordisk (NYSE:NVO) announced new real-world data on Wegovy 2.4 mg, a once-weekly semaglutide injection, in adults with metabolic dysfunction-associated steatohepatitis, known as MASH. The results come from two retrospective studies, PLATINUM-Truveta and RHODIUM-2, presented at the American Association for the Study of Liver Diseases' Liver Meeting 2026 in Denver. The company, headquartered in Plainsboro, New Jersey and Bagsvaerd, Denmark, said the findings help illustrate treatment outcomes in patients with the disease.

The PLATINUM-Truveta Study

PLATINUM-Truveta included 2,873 adults with MASH who started treatment with semaglutide 2.4 mg and 2,285 adults with MASH who started treatment with resmetirom. The adjusted outcomes were measured at three and six months. At three months, AST, a liver enzyme, fell by 6.7 units in the semaglutide group compared with 1.9 units in the resmetirom group, a difference with a p value below 0.001. ALT declined by 8.7 units compared with 4.8 units, although that difference did not reach statistical significance, with a p value of 0.077.

Body weight changes were larger in the semaglutide group, falling 10.5 pounds at three months compared with 1.5 pounds for resmetirom. HbA1c, a measure of blood sugar, decreased 0.29 percentage points with semaglutide, while it rose slightly with resmetirom. At six months, the company reported a mean weight loss from baseline of 18.9 pounds, or about 8%, for semaglutide relative to resmetirom, which it described as statistically significant.

The RHODIUM-2 Analysis

A separate analysis, RHODIUM-2, examined people who began semaglutide 2.4 mg compared with those who did not start the treatment. The company reported that patients who started semaglutide had greater one-year reductions in liver enzymes and body weight, along with a larger decrease in HbA1c, than patients who did not start it. The study design differs from a randomized trial, and the comparison groups reflect treatment decisions made in routine care.

Both analyses are retrospective. That design allows researchers to review existing patient records, but it cannot control for every Factor that influences treatment choices or outcomes, which limits how the results can be compared with controlled clinical trials.

Context Around the MASH Treatment Landscape

The company said the disease may progress without clear symptoms, which makes it important for clinicians and patients to understand how a treatment may affect the condition over time. Novo Nordisk's vice president of medical affairs said the findings offer insights into real-world results and are intended to inform providers.

Resmetirom is the comparator used in PLATINUM-Truveta, and the study was designed to set semaglutide against an established alternative treatment for the same condition. The company presented the results as real-world data intended to help inform providers, and it did not present them as a replacement for controlled trial findings.

MASH, or metabolic dysfunction-associated steatohepatitis, is a form of liver disease linked to metabolic conditions such as obesity and type 2 diabetes. Liver enzymes such as AST and ALT are commonly tracked in patients with the condition, and changes in these markers are one of several measures used in clinical and real-world research. The company's studies also measured weight and HbA1c, which matter for patients who have overlapping metabolic conditions.

Real-world studies use data from routine clinical care rather than from controlled trials with assigned treatments. They can show how a treatment performs across a broader set of patients, but they also carry limitations, including differences in who receives each treatment. The company presented PLATINUM-Truveta and RHODIUM-2 as real-world analyses, which places them in a different category from pivotal trial results.

Final Word

Novo Nordisk's real-world data on Wegovy 2.4 mg add to the body of observational evidence on liver enzymes, weight and blood sugar in adults with MASH. The PLATINUM-Truveta comparison shows changes in several measures over three and six months, while RHODIUM-2 compares patients who started treatment with those who did not. Because both studies are retrospective, the findings will be read alongside controlled trial results as clinicians and researchers review the evidence.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.